<DOC>
	<DOCNO>NCT02039726</DOCNO>
	<brief_summary>The primary objective study determine whether quizartinib monotherapy prolongs overall survival ( OS ) compare salvage chemotherapy subject FMS-like tyrosine kinase 3 - Internal Tandem Duplication ( FLT3-ITD ) positive AML refractory relapse within 6 month , first-line AML therapy .</brief_summary>
	<brief_title>( QuANTUM-R ) : An Open-label Study Quizartinib Monotherapy vs. Salvage Chemotherapy Acute Myeloid Leukemia ( AML ) Subjects Who Are FLT3-ITD Positive</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Provision write informed consent approve Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) privacy language accordance national regulation ( e.g. , Health Insurance Portability Accountability Act [ HIPAA ] authorization United States [ US ] sit ) prior study related procedure , include withdrawal prohibit medication applicable . 2 . Age ≥ 18 year minimum legal adult age ( whichever great ) time Informed consent . 3 . Morphologically documented primary Acute Myeloid Leukemia ( AML ) AML secondary Myelodysplastic Syndrome ( MDS ) , define World Health Organization ( WHO ) criterion , determine pathology review study site . 4 . In first relapse ( duration remission 6 month less ) refractory prior therapy , without HSCT . Induction therapy must include least 1 cycle anthracycline/mitoxantronecontaining induction block standard dose . 5 . Presence FLT3ITD activate mutation bone marrow peripheral blood ( allelic ratio determine central laboratory cutoff &gt; 3 % FLT3ITD/total FLT3 ) . If specimen send FLT3ITD test central laboratory subject require treatment AML central FLT3_ITD test result available , local test result may acceptable randomization consultation Medical Monitor . 6 . Eligibility preselected salvage chemotherapy , accord Investigator 's assessment . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 8 . Discontinuation prior AML treatment start study treatment ( except hydroxyurea treatment control leukocytosis ) least 2 week cytotoxic agent , least 5 halflives non cytotoxic agent . 9 . Serum creatinine ≤1.5×upper limit normal ( ULN ) , glomerular filtration rate &gt; 25 mL/min , calculate CockcroftGault formula . 10 . Serum potassium , magnesium , calcium ( serum calcium correct hypoalbuminemia ) within institutional normal limit . Subjects electrolytes outside normal range eligible value correct upon retesting follow necessary supplementation . 11 . Total serum bilirubin ≤1.5×ULN . 12 . Serum aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) ≤2.5×ULN . 1 . Acute Promyelocytic Leukemia ( AML subtype M3 ) . 2 . AML secondary prior chemotherapy neoplasm , except AML secondary prior Myelodysplastic Syndrome ( MDS ) . 3 . History another malignancy , unless candidate diseasefree least 5 year . 4 . Persistent , clinically significant &gt; Grade 1 nonhematologic toxicity prior AML therapy . 5 . Clinically significant graft versus host disease ( GVHD ) GVHD require initiation treatment treatment escalation within 21 day , and/or &gt; Grade 1 persistent clinically significant non hematologic toxicity relate HSCT . 6 . History current , central nervous system involvement AML . 7 . Clinically significant coagulation abnormality , disseminate intravascular coagulation . 8 . Prior treatment quizartinib participate prior quizartinib study . 9 . Prior treatment FLT3 target therapy include sorafenib investigational FLT3 inhibitor ( include multikinase inhibitor , midostaurin ) . 10 . Major surgery within 4 week prior screen . 11 . Radiation therapy within 4 week prior screen . 12 . Uncontrolled significant cardiovascular disease 13 . Active infection well control antibacterial antiviral therapy . 14 . Known infection human immunodeficiency virus , active hepatitis B C , active clinically relevant liver disease . 15 . Unwillingness receive infusion blood product accord protocol . 16 . In man whose sexual partner woman childbearing potential , unwillingness inability man woman use highly effective contraceptive method entire study treatment period least 3 month study completion . Male subject must freeze donate sperm start Screening throughout study period , 105 day final study drug administration . 17 . In heterosexually active woman childbearing potential , unwillingness inability use highly effective contraceptive method entire study treatment period least 3 month study treatment completion . Additionally , woman randomize chemotherapy , unwillingness adhere restriction respective locally establish guideline local approve label ( prescribe information , Summary Product Characteristics , US product insert ) manufacturer Patient Information Leaflet ( package insert ) instruct Investigator . 18 . Pregnancy . 19 . Female Subjects must agree breastfeed time Screening throughout study period , 25 day final study drug administration . 20 . Medical condition , serious intercurrent illness , circumstance , Investigator 's judgment , could jeopardize candidate 's safety study subject , could interfere study objective . 21 . For subject UK : Refusal permission allow subject 's General Practitioner notify participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>FMS-like tyrosine kinase 3</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>Quizartinib</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Tablets</keyword>
</DOC>